CVRX
What one share of CVRx holds
Surgical and Medical Instruments and Apparatus
CVRx is a commercial-stage medical device company focused on developing, manufacturing, and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular disease. Barostim is the first medical technology approved by the U.S.
CVRx’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.33 |
|---|---|
| Profit | −$1.97 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$1.56 |
| Cash and investments | $2.42 |
| Debt | $2.20 |
| Book value | $0.75 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $15.64 | −$37.01 | $0.80 | −$42.39 | — | −$813.62 |
| 2021 | $1.26 | −$4.16 | $0.11 | −$2.79 | — | $7.16 |
| 2022 | $1.09 | −$2.02 | $0.03 | −$2.11 | — | $5.28 |
| 2023 | $1.89 | −$1.99 | $0.03 | −$1.91 | — | $3.64 |
| 2024 | $2.27 | −$2.65 | $0.06 | −$1.79 | — | $2.81 |
| 2025 | $2.17 | −$2.04 | $0.02 | −$1.56 | — | $1.49 |